FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914901395> ?p ?o ?g. }

• W2914901395 endingPage "2426" @default.
• W2914901395 startingPage "2426" @default.
• W2914901395 abstract "Abstract Thrombopoietin receptor agonists (TRA) have shown efficacy in clinical trials for patients with immune thrombocytopenia (ITP), achieving initial response rates of up to 88%. However, there is limited research on the effectiveness of TRA in routine clinical practice. The primary objective of this retrospective, observational study was to describe the proportion of patients who achieve platelet counts [plts] ≥30,000/µl within 12 weeks of TRA initiation (treatment response; R). Secondary objectives of this study were to assess the safety and tolerability of TRA, the duration of treatment, maintenance of R, whether patients are able to come off treatment (TRA discontinuation) and, whether different treatment responses are observed in primary versus secondary ITP. Patients aged ≥ 18 years with ITP (primary or secondary) who had initiated TRA (eltrombopag [EPG] or romiplostim [RPM]) treatment ≥4 months prior to data collection were included in the study from UK secondary and tertiary care centres. Data on patient characteristics, disease history, TRA treatment pathways, response to treatment and adverse events (AEs) were collected from medical records (observation period from date of ITP diagnosis to data collection). Overall 267 eligible patients from 15 centres were included (primary ITP n=218, secondary ITP n=49); 42% (n=112/267) and 58% (n=155/267) of patients received EPG and RPM respectively as the first prescribed TRA. The study sample comprised 52% females (n=139/267); median (interquartile range [IQR]) age at TRA initiation was 56 years (40-70). The median (IQR) time from diagnosis of primary and secondary ITP to first TRA treatment was 4.0 years (0.9-11.7) and 1.9 years (0.2-9.5), respectively. 26% (n=57/ 218) of patients with primary ITP and 46% (n=22/48, no diagnosis date recorded for n=1) of patients with secondary ITP received their first TRA within 1 year of diagnosis. Proportion of patients achieving and maintaining R, discontinuing treatment and median time to achieve first R for all patients are described in the table below. 23% (n=61/267) of all patients received both TRAs during the observation period, with 10% (n=6/61, n=5 initiated with RPM) patients switching to receive both TRAs at the same time. 23% (n=36/155) of all patients initiated on RPM switched to EPG and 22% (n=25/112) of all patients initiated on EPG switched to RPM. AEs (related to the use of TRA) were recorded in 33% (n=31/95) and 23% (n=28/123) of patients with primary ITP receiving EPG and RPM respectively. 12% (n=31/267) of all patients discontinued their initial TRA due to poor response (n=20), adverse events (n=7) or complications (n=4). Of the remaining 236 patients, 20% (n=48/236) patients discontinued their initial TRA due to physician/patient request (n=31) or for an unrecorded reason (n=17). 8% (n=14/267) patients discontinued their initial TRA due to reasons other than those listed above and data was unavailable for 2% (n=6/267) patients. 17% (n=36/218) of patients with primary ITP discontinued TRAs within one year of initiation (15% [n=14/95] on EPG and 18% [n=22/123] RPM). 39% (n=19/49) of patients with secondary ITP discontinued TRA within one year of treatment initiation (47% [n=8/17] on EPG and 34% [n=11/32] RPM). 67% (n=147/218) of patients with primary ITP and 43% (n=21/49) of patients with secondary ITP were still receiving a TRA at the time of data collection. Of the 237 patients achieving R, 21% (n=49/236) discontinued TRA treatment within one year of initiation. The median (IQR) time to discontinuation of TRA after achieving R for all patients, was 34 (13 - 97) weeks. The results from this retrospective observational study suggest that patients with primary and secondary ITP respond to TRA in real world settings in a manner that is consistent with results from clinical trials. These results also show that greater proportions of patients with secondary ITP are able to discontinue TRA treatment within one year of initiation suggesting the benefit of these treatments in ITP patient care. Table. Table. Disclosures Cooper: Amgen, Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Provan:Amgen, Novartis: Honoraria, Research Funding. Scully:Novartis: Honoraria, Other: Member of Advisory Board, Speakers Bureau. Grech:Novartis: Other: sponsorship for scientific meetings. Bagot:Amgen, Novartis: Speakers Bureau. Hill:Novartis: Honoraria; Novartis: Honoraria. Nokes:Bayer, MSD, Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Ramscar:Novartis: Employment. Saunders:pH associates: Employment." @default.
• W2914901395 created "2019-02-21" @default.
• W2914901395 creator A5004832106 @default.
• W2914901395 creator A5005731914 @default.
• W2914901395 creator A5008779503 @default.
• W2914901395 creator A5025130326 @default.
• W2914901395 creator A5033681748 @default.
• W2914901395 creator A5050744232 @default.
• W2914901395 creator A5053225513 @default.
• W2914901395 creator A5062961141 @default.
• W2914901395 creator A5086465480 @default.
• W2914901395 date "2018-11-29" @default.
• W2914901395 modified "2023-10-18" @default.
• W2914901395 title "Real World Use of Thrombopoietin-Receptor Agonists in the Management of Immune Thrombocytopenia in the United Kingdom: Results from the TRAIT Study" @default.
• W2914901395 doi "https://doi.org/10.1182/blood-2018-99-110126" @default.
• W2914901395 hasPublicationYear "2018" @default.
• W2914901395 type Work @default.
• W2914901395 sameAs 2914901395 @default.
• W2914901395 citedByCount "1" @default.
• W2914901395 countsByYear W29149013952022 @default.
• W2914901395 crossrefType "journal-article" @default.
• W2914901395 hasAuthorship W2914901395A5004832106 @default.
• W2914901395 hasAuthorship W2914901395A5005731914 @default.
• W2914901395 hasAuthorship W2914901395A5008779503 @default.
• W2914901395 hasAuthorship W2914901395A5025130326 @default.
• W2914901395 hasAuthorship W2914901395A5033681748 @default.
• W2914901395 hasAuthorship W2914901395A5050744232 @default.
• W2914901395 hasAuthorship W2914901395A5053225513 @default.
• W2914901395 hasAuthorship W2914901395A5062961141 @default.
• W2914901395 hasAuthorship W2914901395A5086465480 @default.
• W2914901395 hasConcept C109159458 @default.
• W2914901395 hasConcept C119060515 @default.
• W2914901395 hasConcept C126322002 @default.
• W2914901395 hasConcept C167135981 @default.
• W2914901395 hasConcept C187212893 @default.
• W2914901395 hasConcept C197934379 @default.
• W2914901395 hasConcept C203092338 @default.
• W2914901395 hasConcept C23131810 @default.
• W2914901395 hasConcept C2776915898 @default.
• W2914901395 hasConcept C2777863708 @default.
• W2914901395 hasConcept C2778375690 @default.
• W2914901395 hasConcept C2778715236 @default.
• W2914901395 hasConcept C2780588981 @default.
• W2914901395 hasConcept C28328180 @default.
• W2914901395 hasConcept C2993327898 @default.
• W2914901395 hasConcept C535046627 @default.
• W2914901395 hasConcept C54355233 @default.
• W2914901395 hasConcept C71924100 @default.
• W2914901395 hasConcept C86803240 @default.
• W2914901395 hasConcept C89560881 @default.
• W2914901395 hasConceptScore W2914901395C109159458 @default.
• W2914901395 hasConceptScore W2914901395C119060515 @default.
• W2914901395 hasConceptScore W2914901395C126322002 @default.
• W2914901395 hasConceptScore W2914901395C167135981 @default.
• W2914901395 hasConceptScore W2914901395C187212893 @default.
• W2914901395 hasConceptScore W2914901395C197934379 @default.
• W2914901395 hasConceptScore W2914901395C203092338 @default.
• W2914901395 hasConceptScore W2914901395C23131810 @default.
• W2914901395 hasConceptScore W2914901395C2776915898 @default.
• W2914901395 hasConceptScore W2914901395C2777863708 @default.
• W2914901395 hasConceptScore W2914901395C2778375690 @default.
• W2914901395 hasConceptScore W2914901395C2778715236 @default.
• W2914901395 hasConceptScore W2914901395C2780588981 @default.
• W2914901395 hasConceptScore W2914901395C28328180 @default.
• W2914901395 hasConceptScore W2914901395C2993327898 @default.
• W2914901395 hasConceptScore W2914901395C535046627 @default.
• W2914901395 hasConceptScore W2914901395C54355233 @default.
• W2914901395 hasConceptScore W2914901395C71924100 @default.
• W2914901395 hasConceptScore W2914901395C86803240 @default.
• W2914901395 hasConceptScore W2914901395C89560881 @default.
• W2914901395 hasIssue "Supplement 1" @default.
• W2914901395 hasLocation W29149013951 @default.
• W2914901395 hasOpenAccess W2914901395 @default.
• W2914901395 hasPrimaryLocation W29149013951 @default.
• W2914901395 hasRelatedWork W1966937027 @default.
• W2914901395 hasRelatedWork W2026416582 @default.
• W2914901395 hasRelatedWork W2182308824 @default.
• W2914901395 hasRelatedWork W2560284078 @default.
• W2914901395 hasRelatedWork W2937646700 @default.
• W2914901395 hasRelatedWork W3015587704 @default.
• W2914901395 hasRelatedWork W3188351472 @default.
• W2914901395 hasRelatedWork W4205264472 @default.
• W2914901395 hasRelatedWork W4224737769 @default.
• W2914901395 hasRelatedWork W2604921968 @default.
• W2914901395 hasVolume "132" @default.
• W2914901395 isParatext "false" @default.
• W2914901395 isRetracted "false" @default.
• W2914901395 magId "2914901395" @default.
• W2914901395 workType "article" @default.